266 related articles for article (PubMed ID: 17070499)
1. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
2. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
4. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
9. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
10. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
Zhang W; Guo XY; Deisseroth AB
Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
[TBL] [Abstract][Full Text] [Related]
11. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
13. Activation of p53 DNA binding activity by point mutation.
Marston NJ; Ludwig RL; Vousden KH
Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
[TBL] [Abstract][Full Text] [Related]
14. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
[TBL] [Abstract][Full Text] [Related]
15. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
Srinivasan R; Maxwell SA
Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
[TBL] [Abstract][Full Text] [Related]
16. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
Deppert W; Göhler T; Koga H; Kim E
J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
19. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
Niewolik D; Vojtesek B; Kovarik J
Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
[TBL] [Abstract][Full Text] [Related]
20. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]